191 related articles for article (PubMed ID: 33055462)
41. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
Cordonnier C; Ljungman P; Juergens C; Maertens J; Selleslag D; Sundaraiyer V; Giardina PC; Clarke K; Gruber WC; Scott DA; Schmoele-Thoma B;
Clin Infect Dis; 2015 Aug; 61(3):313-23. PubMed ID: 25870329
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
45. Two new pneumococcal vaccines - Prevnar 20 and Vaxneuvance.
Med Lett Drugs Ther; 2021 Nov; 63(1638):188-190. PubMed ID: 35085216
[No Abstract] [Full Text] [Related]
46. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
47. Distribution and annual changes in the proportion of Streptococcus pneumoniae serotypes in Japanese adults with pneumococcal pneumonia from 2011 to 2017.
Noguchi S; Yatera K; Akata K; Chang B; Ikegami H; Hata R; Yamasaki K; Kawanami T; Mukae H
J Infect Chemother; 2019 Nov; 25(11):925-929. PubMed ID: 31350184
[TBL] [Abstract][Full Text] [Related]
48. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
[TBL] [Abstract][Full Text] [Related]
49. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
[TBL] [Abstract][Full Text] [Related]
50. Cluster randomised controlled trial of an educational outreach visit to improve influenza and pneumococcal immunisation rates in primary care.
Siriwardena AN; Rashid A; Johnson MR; Dewey ME
Br J Gen Pract; 2002 Sep; 52(482):735-40. PubMed ID: 12236277
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
52. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.
Odusanya OO; Kuyinu YA; Kehinde OA; Shafi F; François N; Yarzabal JP; Dobbelaere K; Rüggeberg JU; Borys D; Schuerman L
Hum Vaccin Immunother; 2014; 10(3):757-66. PubMed ID: 24356787
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease.
Fletcher TJ; Tunnicliffe WS; Hammond K; Roberts K; Ayres JG
BMJ; 1997 Jun; 314(7095):1663-5. PubMed ID: 9193290
[No Abstract] [Full Text] [Related]
54. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
[TBL] [Abstract][Full Text] [Related]
55. Factors Associated with Influenza Vaccination of Hospitalized Elderly Patients in Spain.
Domínguez À; Soldevila N; Toledo D; Godoy P; Castilla J; Force L; Morales M; Mayoral JM; Egurrola M; Tamames S; Martín V; Astray J;
PLoS One; 2016; 11(1):e0147931. PubMed ID: 26824383
[TBL] [Abstract][Full Text] [Related]
56. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.
Scheifele DW; McNeil SA; Ward BJ; Dionne M; Cooper C; Coleman B; Loeb M; Rubinstein E; McElhaney J; Hatchette T; Li Y; Montomoli E; Schneeberg A; Bettinger JA; Halperin SA;
Hum Vaccin Immunother; 2013 Nov; 9(11):2460-73. PubMed ID: 23839537
[TBL] [Abstract][Full Text] [Related]
57. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
58. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
[TBL] [Abstract][Full Text] [Related]
59. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Japan after introduction of the routine immunization program.
Miyazaki H; Shibuya R; Midorikawa N; Chang B; Ohnishi M; Matsumoto T
J Infect Chemother; 2017 Apr; 23(4):234-240. PubMed ID: 28161295
[TBL] [Abstract][Full Text] [Related]
60. Lack of effect of influenza and pneumococcal vaccines on anticoagulation by warfarin.
Farrow PR; Nicholson KG
J Infect; 1984 Sep; 9(2):157-60. PubMed ID: 6501905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
